Chemotoxins for Targeted Treatment of Diseased Cells
Posted Dec 01 2011 7:00pm
Description of Invention: Researchers at the National Institute on Aging (NIA) have developed a straightforward method to elicit immune responses to specific cancers and AIDS by using a chemoattractant-based antigen delivery strategy. The strategy uses formulations composed of chemokines fused to toxic moieties (aka “chemotoxins”) to preferentially and specifically eliminate chemokine receptor-expressing cells. The method uses the natural ability of the chemokines to stimulate measurable and improved humoral and immune responses.
Chemokines can be of viral or microbial (B-Defensin) origin.
This method can also be used to cause inflammation to specifically target immune cells to increase immunogenicity for malignant tumors using SPANX-B and Laminin tumor antigens.
Applications:
A potential immunotherapeutic antigen for the treatment of several malignancies including lymphoma, breast, lung, and ovarian.
Use as a monoclonal antibody.
Antigens, such as SPANX-B and Laminin, can also be used as prognostic and diagnostic agents for the monitoring of disease.
Advantages:
In contrast to recombinant proteins, these small peptides can be more easily manufactured.
They help to facilitate the activation of cells in a more specific and therapeutically effective way.
Active immune system will do a better job attacking cancer cells.
Collaborative Research Opportunity: The National Institute on Aging (NIA) is seeking parties interested in collaborative research to further evaluate or commercialize effective vaccines that target bacterial, viral, or tumor antigens. Any or all of the inventions in this announcement are available for co-development and collaboration. For collaboration opportunities, please contact Nikki Guyton, Ph.D. at darackn@mail.nih.gov . Click here to view the NIA collaborative opportunity announcement.
For Licensing Information Please Contact: Patrick McCue Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: McCuepat@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220
Description of Invention:
Researchers at the National Institute on Aging (NIA) have developed a straightforward method to elicit immune responses to specific cancers and AIDS by using a chemoattractant-based antigen delivery strategy. The strategy uses formulations composed of chemokines fused to toxic moieties (aka “chemotoxins”) to preferentially and specifically eliminate chemokine receptor-expressing cells. The method uses the natural ability of the chemokines to stimulate measurable and improved humoral and immune responses.
Applications:
Advantages:
Development Status:
Inventors:
Arya Biragyn (NCI)
Patent Status:
HHS, Reference No. E-194-2000/0
US, , Patent No. 7,897,152, Issued 01 Mar 2011
US, Application No. 13/009,572 filed 19 Jan 2011
Several other U.S. patents have issued and several U.S. patent applications are pending. Inquire for further details.
Relevant Publication:
Collaborative Research Opportunity:
The National Institute on Aging (NIA) is seeking parties interested in collaborative research to further evaluate or commercialize effective vaccines that target bacterial, viral, or tumor antigens. Any or all of the inventions in this announcement are available for co-development and collaboration. For collaboration opportunities, please contact Nikki Guyton, Ph.D. at darackn@mail.nih.gov . Click here to view the NIA collaborative opportunity announcement.
For Licensing Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220
Ref No: 2344
Updated: 12/2011